8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Ultragenyx Pharmaceutical filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- RARE Ultragenyx Pharmaceutical+9.5% 19d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+9.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+4.6% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| RARE | +3.49% | -3.31% | base | after close | after close | after close | after close |
| XLV | -2.42% | +0.36% | base | after close | after close | after close | after close |
| XBI | +1.67% | +0.67% | base | after close | after close | after close | after close |
| LLY | -8.25% | +0.73% | base | after close | after close | after close | after close |
| JNJ | +2.19% | +2.93% | base | after close | after close | after close | after close |
| PFE | -1.47% | +1.94% | base | after close | after close | after close | after close |
| MRK | -1.72% | +4.16% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001193125-26-445342 Size: 547 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.02: Results of Operations and Financial Condition Item 2.05: Cost Associated with Exit or Disposal Activities I…
Source: sec-edgar
The price since 3 Nov 2026: Ultragenyx Pharmaceutical (RARE) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | +2.93% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +2.19% | final price |
| Eli Lilly (LLY) | three days earlier | +0.73% | final price |
| Eli Lilly (LLY) | five days earlier | -8.25% | final price |
| Merck (MRK) | three days earlier | +4.16% | final price |
| Merck (MRK) | five days earlier | -1.72% | final price |
| Pfizer (PFE) | three days earlier | +1.94% | final price |
| Pfizer (PFE) | five days earlier | -1.47% | final price |
| Ultragenyx Pharmaceutical (RARE) | three days earlier | -3.31% | final price |
| Ultragenyx Pharmaceutical (RARE) | five days earlier | +3.49% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.67% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.67% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.36% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.42% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros bought Ultragenyx Pharmaceutical (RARE), worth $1,001 - $15,000 on 29 Sep 2026. That is 35 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Ultragenyx Pharmaceutical (RARE)
Companies mentioned with this story
- RARE Ultragenyx Pharmaceutical
For “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer),” Ultragenyx Pharmaceutical (RARE) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> RARE
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer).” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer).” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer).” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
For “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer),” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
For “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer),” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer).” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
How “8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)” reaches Ultragenyx Pharmaceutical (RARE)
“8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)” (3 Nov 2026) reaches Ultragenyx Pharmaceutical (RARE) through this story.
Ultragenyx Pharmaceutical (RARE) is on the page because SEC 8-K filing -> direct issuer disclosure -> RARE
Select Sector Spdr Tr (XLV) is here too. Its reason reads: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Dates in the story, and the Ultragenyx Pharmaceutical (RARE) price range
RARE traded between 14.35 and 17.62 across 19 sessions. The latest close on file is 16.31.
What the saved facts support for Ultragenyx Pharmaceutical (RARE)
46 out of 100
“8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.